Andrew Hamer joins Cirrus Pharmaceuticals, a Kemwell Company as VP R&D

MORRISVILLE, N.C.--(BUSINESS WIRE)--Cirrus Pharmaceuticals, a Kemwell company, which is a 100% services oriented company providing pharmaceutical contract development and manufacturing services, announced that Andrew Hamer has joined as VP R&D.

"We are excited to have Andrew join Cirrus, a Kemwell Company. Andrew brings a wealth of experience and knowledge in development of products for different dosage forms and will help support our customers' programs and enhance the value we bring to them"
"We are excited to have Andrew join Cirrus, a Kemwell Company. Andrew brings a wealth of experience and knowledge in development of products for different dosage forms and will help support our customers' programs and enhance the value we bring to them" says Karan Bagaria, VP Corporate Development at Kemwell.

"I'm thrilled to have joined Cirrus and feel very privileged to be here. I'm looking forward to working with so many talented people and building on the Cirrus / Kemwell heritage here in RTP to create a world class development organization that will be a partner of choice" says Andrew Hamer, VP R&D.

Andrew has over 20 years' experience in the Pharmaceutical Industry, specializing in respiratory and dermatology products. Andrew previously worked at GlaxoSmithKline as Senior Director R&D Operations in RTP. Prior to GSK, Andrew worked at Cardinal Health in the U.S in a leadership role in their pulmonary and nasal department. Before his time in the U.S., Andrew spent time in the respiratory development groups at Sanofi-Aventis and Covance Laboratories in the UK. Andrew gained his MSc in Scientific Instrumentation from Manchester Metropolitan University and BSc in Chemistry from University Central Lancashire.

About Cirrus, a Kemwell company:

Cirrus, a contract product development organization based in RTP, NC, USA, was acquired by Kemwell in 2013. Kemwell is a 100% CDMO, servicing pharmaceutical and biopharmaceutical organizations worldwide for over 30 years. With integrated facilities in India, Sweden and the US, Kemwell delivers a full portfolio of services for sterile and non-sterile products from pre-formulation to commercial supply worldwide. Our 1200+ global workforce offers proven expertise in inhaled, nasal, oral, parenteral and topical dosage forms.

Read more about on www.cirruspharm.com and www.kemwellpharma.com.

Contacts

Cirrus Pharmaceuticals
Karan Bagaria, 919-884-2064
[email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.